The US Court of Appeals for the Second Circuit has heard arguments surrounding whether Actavis should be allowed to discontinue its first Alzheimer’s drug Namenda to make way for an extended release version of the medicine.
The US Patent Trial and Appeal Board has instigated an interference proceeding between Biogen and Forward Pharma to determine who first invented a treatment for multiple sclerosis.
Israeli pharmaceutical company Teva has, in one single filing, accused five generic drug makers of infringing a patent covering its blockbuster multiple sclerosis drug Copaxone.
The US Court of Appeals for the Federal Circuit has upheld the validity of four patents covering conjunctivitis treatment AzaSite.
The US House of Representatives Judiciary Committee will hold a hearing on the Innovation Act tomorrow, during which testaments will be given by representatives from Eli Lilly and the Biotechnology Industry Organization.
Dallas-based hedge fund Hayman Capital Management has defended its owner’s decision to challenge a clutch of patents using the inter partes review procedure.
Patent and trademark attorney firm Murgitroyd has boosted its intellectual property team by promoting Michael Marchant to director.
The US Court of Appeals for the Federal Circuit has upheld a district court’s decision to invalidate a patent covering arthritis treatment Humira, after a challenge by biopharmaceutical company AbbVie.
A US hedge fund manager and a company he created has taken aim at Jazz Pharmaceuticals in an inter partes review patent challenge, marking the third time he has challenged a company’s patents.
Merck Sharp & Dohme has sued Apotex at the US District Court for the District of New Jersey for allegedly infringing a patent covering hay fever nasal spray Nasonex.